Intellectual Capital
Embracing Technology. Facilitating Digital Transformation.
Continually upgrading technology to build a seamless digital ecosystem
Diagnostic testing calls for constant research and development and upgradation of testing techniques. We are in search of advanced solutions to provide diagnostic testing to our patients. Our state-of-the-art technology attracts customers for its easy sample collection and accuracy in test results. We are constantly endeavoring to upgrade our testing methods and technology to deliver the best test results to our customers.
Digital ecosystem to enhance customer experience
At Metropolis, we are building a comprehensive digital ecosystem for all our clients, partners and medical professionals. We have fully integrated and automated procedures ranging from registration, bar-coding and billing to analysis and reporting of test results with the help of our information technology system.
Standardization
Achieve standardization across our operationsReduced errors
Reduce incidences of errors due to human interventionTechnical operations
Monitor technical operations through enhanced IT systemsPerformance metrics
Track our key performance metrics closelyPatients and customers
Provide convenience to our patients and customers by allowing them to book appointments, complete registration and access test reports onlineDigital transformation of our business
Our plans
- Enable a fully scaled application programing interface (API) centric tech core
- Integrate full-fledged customer relationship management (CRM) stack for service, sales and marketing with customer data platform
- Install omni-screen point-of-sale application for registration and invoicing
- Install newly architected LIS with middleware for auto validation
- Enhance B2C App
- Install a directory of services 2.0 (DOS) for faster creation of products and packages
- Integrate supply chain (SCM 2.0) with visibility of consumption and planning
- Enable a B2B portal (partner portal) adoption drive
- Consolidate cloud data center
- Acquire near real-time business intelligence
Advantages of Digital Transformation
Digital leadership
Faster go-to-market
Easier integration with government and private entities (Ayushman Bharat Digital Mission, aggregators, hospitals)
Omni-channel acquisition and zero loss of business at touchpoints
Improving turnaround time (TAT)
360-degree view of customers
Data-driven business (analytics)
Improving net promoter score (NPS)
Emerged as an end-to-end digital service provider of diagnostic tests
Our goal is to establish Metropolis as an end-to-end digital service provider for all of our stakeholders, including clients, vendors and partners in the healthcare industry.
Digital customer engagement
Planned to launch an end-to-end online journey for customers on the Metropolis website and app
Digital doctor experience
Launched a chatbot (Metrobot) to support doctors in providing enhanced services to patients
Optimizing online presence
Optimized digital presence across search and local discovery services to drive customers in our centers
Digitalizing distribution and logistics
Launched a unified patient information system, leading to reduced time for data entry, processing and enhanced staff productivity
Digitalizing customer support
Launched custom-built CRM to provide omni-channel customer support with high agent productivity
Enabling our phlebotomists
Planned to launch a ‘Home-visit’ app for our phlebotomists, leading to higher productivity and enhanced customer experience
Building a scientific leadership brand
- New tests on advanced technologies: AI Driven Multiplex Nanotechnology Array, LCMS, CGH Array, and WSI
- NGS Tests launched (NextGen NIPT- Non-Invasive Prenatal Screening test, NextGen BRCA, NextGen HLA Typing, Next Gen Cancer Hotspot panel 50, Next Gen Oncomine Focus Assay) and more in pipeline
- Companion Diagnostics CDx
- Artificial Intelligence
- Women and Child
- Oncology
- Chronic Disease
- Molecular Genomics
83
200
10,000
20,000
Innovation is in our DNA
Being a leader in diagnostics, Metropolis has always been at the forefront in introducing various technologies, tests and platforms that can directly ensure an accurate timely diagnosis to the patient. In line with this, the Company launched the Metropolis Innovation Cell to focus on Molecular Genomics, Superspeciality Pathology, and Companion Diagnostics. The goal has been to nurture and expand the scope for Oncology, Prenatal testing, Transplant Immunology, infectious and chronic diseases through Next Generation Sequencing and Artificial Intelligence.
KEY COMPLEX TESTS LAUNCHED
-
NextGen NIPT- Non-Invasive Prenatal Screening test is a more advanced method for prenatal screening that uses circulating DNA from maternal blood and advanced genomics platforms of Next Generation Sequencing (NGS) combined with bioinformatics algorithms to predict the risk of chromosomal disorders such as Down’s syndrome (T21), Edward Syndrome (T18), Patau Syndrome (T13), Turner’s syndrome (Monosomy X) etc., more accurately than traditional maternal biomarker screening tests.
-
NextGen BRCA for Breast Cancer: It’s a preventive Genetic Testing for Breast Cancer which uses the Next Generation Sequencing (NGS) Technology to analyze genes to see if there are any mutations that may increase the risk of cancer. Mutations or abnormalities in the BRCA1 and BRCA2 genes are the most common cause of hereditary breast and ovarian cancer although there are other genes identified. This brings a higher risk of getting cancer at a younger age in men and women.
-
NextGen HLA Typing: Powered by the complex molecular technology ‘Next Generation Sequencing (NGS)’, Metropolis’ NextGen HLA Typing is a high-resolution molecular test, which is performed for Hematopoietic Stem Cell Transplant (HSCT) & Solid organ transplantation. This test aids in the identification of a suitable donor for bone marrow, cord blood, or organ transplant by analyzing the Human Leukocyte Antigen (HLA) genes that a person has inherited from the parents.
-
AI-powered Allergy Component Testing: Launched a novel testing platform based on Component Resolved Diagnostics (CRD) to support India’s population in diagnosing various forms of allergies. This 4th generation allergy testing technology uses Artificial Intelligence to assist clinicians in making sound clinical decisions and provides great insights into selecting and optimizing the course of treatment regarding an individual’s allergic disease. The test, powered by a Nanotechnology based Multiplex system utilizing molecular components can easily detect specific IgE antibodies against 295 different allergens, using a simple blood test and provides results for 158 food allergens, 127 respiratory allergens and 10 contact allergens
Leveraging IT for competitive advantage
Improving business revenue generation capabilities
- CDP & Marketing Automation providing Omni Channel Campaign Capability is expected to enhance lead generation
- Backend automation would drive quicker fulfilment and improved conversion
- Unified Profiling of customers would lead to greater cross-selling and upselling opportunities
Cost saving and optimization
- Digital Channels for B2B & D2C Engagements would optimise cost of servicing & operations
- Cloud consolidation would optimize better return from assets
- Consolidation of vendors would lead to synergy and productivity
Improved operational efficiency
- Service CRM implemented for quicker redressal of Query/Request/Complaints for improving NPS
- Tech-stack uptime better than 99.5% with enhanced security to ensure zero data loss across operations
- Implementation of sample tracking process to improve the visibility of customers’ turnaround time (TAT) for reports’ delivery
- Introduction of a Learning Management System tailored to training and development goals Automated Quality System to track quality standards across the group
- Feedback management aimed to increase the percentage of patients providing instant feedback and rating
